In December 2018, Immedica acquired the rights for the products Ammonaps® (Sodium phenylbutyrate) and Ravicti® (Glycerol phenylbutyrate), from Horizon Therapeutics in all territories outside North America and Japan.
On June 6, 2019, Immedica became the Market Authorization Holder (MAH) for Ammonaps® and Ravicti®, in 28 EU member countries, Norway and Iceland.
As a next step for this business, Immedica will from 1 January 2020 start to distribute Ravicti® and Ammonaps® in Europe and the Middle East. Until December 31, 2019, Immedica will continue the collaboration with Sobi as its distribution partner in Europe and the Middle East.
“We are grateful for the efforts Sobi has put down in launching Ravicti and managing Ammonaps for many years. However, we now have the right capabilities in place across Europe and Middle East, and it is therefore a natural step for us to continue to drive the commercialization of both Ammonaps and Ravicti in the territories ourselves.” says Anders Edvell, CEO of Immedica. “We are now looking forward to working together with the dedicated health care specialists managing urea cycle disorders with the ultimate aim to ensure the best possible treatment for the patients with these diseases in all of our territories,” concludes Anders Edvell.
About Urea Cycle Disorders (UCD)
The urea cycle is a process in which waste (ammonia) is removed from the body. When you eat proteins, the body breaks them down into amino acids. Ammonia is produced from leftover amino acids, and it must be removed from the body.
Several inherited conditions can cause problems with this waste-removal process. People with a urea cycle disorder are missing a gene that makes the enzymes needed to break down ammonia in the body. As a group, these disorders occur in 1 in 30,000 newborns in the territories where Immedica has the product rights.
Typically, symptoms such as confusion, nausea, vomiting, decreased food intake and increased sleepiness occur within the first week after birth.
About Immedica Pharma
Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East.
Immedica provides significant know-how and experience from commercialization of niche/specialty care products across Europe and the Middle East, and the company’s management team has an outstanding track record of operating niche pharma products internationally. Immedica has capabilities to provide optimal access of specialty care medicines to patients with significant medical needs, including key areas such as regulatory affairs, pharmacovigilance, medical affairs, pricing & reimbursement, quality and product distribution.
Immedica’s main owner is Impilo AB, a private Nordic investment company established in 2017, with more than SEK 3.6 billion in committed capital from leading Nordic and international investors.
For more information
Anders Edvell, CEO, Immedica
+46 705 44 61 26